Related Experiment Video

Updated: Jul 14, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line

Céline Bertrand-Thiebault1, Christine Masson, Gérard Siest

  • 1INSERM, U525, Equipe 4, Univ Henri Poincaré, Nancy I, Nancy, F-54000 France.

Journal of Cardiovascular Pharmacology
|May 22, 2007
PubMed

Insights

Statins impact cytochrome P450 (CYP) expression in endothelial cells. Lovastatin and fluvastatin significantly increased CYP2C9 protein levels, suggesting a role for the CAR receptor in this vascular response.

Area of Science:

  • Vascular Biology
  • Pharmacology
  • Biochemistry

Background:

  • Endothelial and smooth muscle cells are key components of blood vessels, influencing vascular structure and function.
  • Statins, or 3-hydroxymethyl coenzyme A reductase inhibitors, are crucial for vascular health and are metabolized by cytochrome P450 (CYP) enzymes.
  • Both endothelial and smooth muscle cells are involved in producing vasoactive compounds from arachidonic acid.

Purpose of the Study:

  • To investigate the effects of various statins on cytochrome P450 (CYP) expression specifically within endothelial cells.
  • To determine the role of nuclear receptors, CAR and PXR, in mediating statin-induced CYP expression in endothelial cells.

Main Methods:

  • Treatment of human endothelial cells with different statins (e.g., lovastatin, fluvastatin).
  • Analysis of CYP expression, including CYP2C9, and nuclear receptor (CAR, PXR) levels via protein analysis.
  • Incubation periods of up to 96 hours to assess sustained effects.

Main Results:

  • Endothelial cells express CYPs responsible for producing epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs).
  • Treatment with lovastatin elevated CYP2C9 expression.
  • Fluvastatin and lovastatin significantly increased CYP2C9 protein levels after 96 hours.
  • CAR was expressed in endothelial cells, while PXR was not.

Conclusions:

  • Statins, specifically lovastatin and fluvastatin, upregulate CYP2C9 expression in endothelial cells.
  • The observed upregulation of CYP2C9 by statins in endothelial cells is likely mediated through the Constitutive Androstane Receptor (CAR) due to the absence of PXR expression.

More Related Videos

Evaluation of Bioenergetic Function in Cerebral Vascular Endothelial Cells06:15

Evaluation of Bioenergetic Function in Cerebral Vascular Endothelial Cells

Published on: November 19, 2016

Endothelial Cell Transcytosis Assay as an In Vitro Model to Evaluate Inner Blood-Retinal Barrier Permeability10:56

Endothelial Cell Transcytosis Assay as an In Vitro Model to Evaluate Inner Blood-Retinal Barrier Permeability

Published on: June 7, 2022

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...